Breast cancer is a universal disease in women worldwide and the leading cause of cancer fatality rate among women. Therefore, it is imminent to find potential biomarkers and functional targets that can be applied to individualized precision therapy to reduce mortality. Glucose metabolism disorder is a universal feature of cancer. However, long non-coding RNA (lncRNAs) may play an important role in this process. A few critical enzymes, such as hexokinase, pyruvate kinase M, and lactate dehydrogenase, that affect glycolysis, oxidative phosphorylation, and pentose phosphate pathway were used to promote the metastasis and invasion of cancer cells by lncRNAs. Unusual glycosylation positively promotes tumor progression and is a biomarker of cancer. Clinically, specific glycosylation of glycoproteins is defined as a tumor biomarker.
Fig.1 A co-expression network of glucose metabolism-related lncRNAs and glucose metabolism-related genes. (Xu, et al., 2023)
At CD BioGlyco, our team consists of specialized chemical scientists and engineers with a wealth of experience and in-depth knowledge. Our Glycogenomics Platform combines advanced methods and techniques that are used to custom glycogene discovery service in breast cancer. The services we provide include but are not limited to:
Fig.2 Glycogene discovery in breast cancer. (CD BioGlyco)
CD BioGlyco has enriched the Cancer Glycogene Discovery Service to cover our client's essential needs and we continue to conduct research and expand our service area to help our clients achieve their goals. Welcome to contact us for custom service. We look forward to your happy cooperation.